$XBI $128 +2%
ASCO Abstract Release Movers
$SNSE +30% SNS-301 (immunoPhage) - POC - HNSCC 1PR/7SD anti-PD1 fail pts
$PDSB +26% PDS101, M7824 + NHS-IL12 83%ORR HPV+ & 63% HPV- advancd cancer checkpoint fail pts.
$IMMP +16% Efti + pembro 27% ORR in NSCLC and 11% CR and 20%PR in HNSCC
$MRUS -16%
$ALPN -17%
$BDTX -37%
Covid Updates
$SRNE +4% Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome. source
$IMNM -1% Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern. source
$BTNX +2% Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine. source
$BTNX +2% Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®. source
Pipeline Updates
$AUPH +3% Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis. source
$OMER -11% OMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA. source
$ACRX +6% AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease. source
$ANIX +6% Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application. source
$XENT +1% Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery. source
$OBSV +4% ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids. source
$SRNE +4% Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device. source
$BPMC +4% Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors. source
$IMGN -2% ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status. source
$ALLO -5% Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021. source
Finance Updates
$YMAB +8% Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America. source
Posted by DV
Comments